Abstract
Molecular biomaterials such as natural and sythesized biodegradable polymers are material basis in development of nanomedicine, which can be defined as applocation and further development of nanotechnology to solve the problems in medicine, i.e. to diagnose, treat and prevent diseases at cellular and molecular level. This presentation will demonstrate through a series of proof-of-concept experimental results how the model drugs such as Paclitaxel and Docetaxel formulated in nanoparticles of biodegradable polymers can result in high cellular uptake, long half-life in circulation, desired pharmacokinetics and biodistribution, enhanced therspeutic effects and reduced side effects. The same philosophy can also be applied to delivery other diagnostic and therapeutic agents, from which the various brunches of nanomedicine such as nanoimmunotherapy, nanothermotherapy, nanophototherapy, nanoradiotherapy, siRNA-based nanomedicine, etc are emerging for future medicine. This seminar is supported by Tsinghua University Overseas Collaborative Program on Topics at the Cutting Edge （此讲座由清华大学海外高端合作项目资助， 特此鸣谢！）

About the Speaker
Prof FENG Si-Shen graduated with a 6-year diploma from Peking University. He obtained his Master Degree from Tsinghua University in 1981 and PhD from Columbia University in 1988. He completed his postdoctoral training in Columbia University School of Physicians & Surgeons and then worked as a research scientist in Department of Biochemistry, Cellular & Molecular Biology, Northwestern University. He joined National University of Singapore Sep 1996. His research interests include cellular and molecular biomechanics, biomembranes,  molecular biomaterials, chemotherapeutic engineering, cancer nanotechnology and nanomedicine. Prof Feng is an Associated Editor of Biomaterials (JIF=8.312) and Nanomedicine (JIF=5.824). He is also involved in the editorial board of other journals such as Nanomedicine-NBM and Intl J Nanomedicine, J Biomedical Nanotechnology, etc. He has been ranked by SCI Author Analysis as #1 in the three emerging areas of Nanomedicine, Cancer Nanotechnology and Pharmaceutical Nanotechnology respectively.